StreetInsider.com News Articles

Form 144 CytoMed Therapeutics Filed by: mDR Ltd

Thu, 12 Feb 2026 09:04:00 -0500

si-local-file:///var/storage/secattach/20260212/25988479.html

Form 144 CytoMed Therapeutics Filed by: mDR Ltd

Thu, 12 Feb 2026 09:04:00 -0500

si-local-file:///var/storage/secattach/20260212/25988479.html

Form 6-K CytoMed Therapeutics For: Jan 28

Wed, 28 Jan 2026 11:41:00 -0500

si-local-file:///var/storage/secattach/20260128/25906673.html

Form 6-K CytoMed Therapeutics For: Jan 28

Wed, 28 Jan 2026 11:41:00 -0500

si-local-file:///var/storage/secattach/20260128/25906673.html

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

Wed, 28 Jan 2026 10:00:00 -0500

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company’s research programs, clinical progress, and operations.

CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

Wed, 28 Jan 2026 10:00:00 -0500

CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and

CytoMed seeks shareholder input on cell therapy access proposal

Tue, 13 Jan 2026 08:05:22 -0500

CytoMed Therapeutics Limited (NASDAQ: GDTC) announced it will seek shareholder feedback on a proposal allowing shareholders to access the company's cell therapies using their shareholdings, subject to doctor approval and home country regulations.

The Singapore-based biopharmaceutical company reported it has sufficient resources to fund operations for at least one year through its low-cost Southeast Asian infrastructure. The company stated it may pursue licensing and real estate asset monetization as additional funding sources.

CytoMed entered a memorandum of understanding with Universiti Malaya in December 2025 to establish a Phase I clinical trial in Malaysia testing its unmodified gamma delta T cells for cancer

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

Tue, 13 Jan 2026 08:00:00 -0500

SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing,

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

Tue, 13 Jan 2026 08:00:00 -0500

Form 6-K CytoMed Therapeutics For: Jan 13

Tue, 13 Jan 2026 08:00:00 -0500

si-local-file:///var/storage/secattach/20260113/25841023.html

Form 6-K CytoMed Therapeutics For: Jan 13

Tue, 13 Jan 2026 08:00:00 -0500

si-local-file:///var/storage/secattach/20260113/25841023.html

CytoMed partners with Malaysia hospital for cancer cell therapy trial

Mon, 08 Dec 2025 08:03:24 -0500

CytoMed Therapeutics Limited (NASDAQ: GDTC) announced it entered into a memorandum of understanding with Universiti Malaya Medical Centre to establish a Phase I clinical trial in Malaysia. The trial will investigate the safety and efficacy of the company's allogeneic gamma delta T cells for cancer patients with no treatment options.

The Singapore-based biopharmaceutical company's treatment uses unmodified gamma delta T cells derived from healthy donors without genetic modification. This approach differs from autologous therapies that use a patient's own cells, according to the company's announcement.

The Malaysia trial complements CytoMed's ongoing Phase I trial at National University Hospital Singapore, which tests genetically

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogene

Mon, 08 Dec 2025 08:00:00 -0500

SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”) a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogene

Mon, 08 Dec 2025 08:00:00 -0500

Form 6-K CytoMed Therapeutics For: Dec 08

Mon, 08 Dec 2025 08:00:00 -0500

si-local-file:///var/storage/secattach/20251208/25709746.html

Form 6-K CytoMed Therapeutics For: Dec 08

Mon, 08 Dec 2025 08:00:00 -0500

si-local-file:///var/storage/secattach/20251208/25709746.html

CytoMed completes acquisition of T cell technology for China market

Tue, 18 Nov 2025 08:00:54 -0500

CytoMed Therapeutics Limited (NASDAQ: GDTC) completed the acquisition of allogeneic gamma delta T cell technology from TC BioPharm Limited, a subsidiary of TC BioPharm (Holdings) PLC (OTC: TCBPY), according to a company statement.

The acquired technology, designated TCB-002, previously completed a Phase I clinical trial in Europe and received orphan drug designation from the U.S. Food and Drug Administration for treating Acute Myeloid Leukemia.

CytoMed plans to use the technology to develop cancer treatments for China and India markets. The Singapore-based company is in discussions with prospective partners to develop a manufacturing method for donor-derived gamma delta T cells using cytokines rather

CytoMed completes acquisition of T cell technology for China market

Tue, 18 Nov 2025 08:00:54 -0500

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

Tue, 18 Nov 2025 08:00:00 -0500

SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology (termed “TCB-002”) of TC BioPharm Limited (“TCBL”), a subsidiary of TC BioPharm (Holdings) PLC (OTC:TCBPY). This follows CytoMed’s announcement on October 14, 2025 regarding its proposed

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

Tue, 18 Nov 2025 08:00:00 -0500

Form 6-K CytoMed Therapeutics For: Nov 18

Tue, 18 Nov 2025 08:00:00 -0500

si-local-file:///var/storage/secattach/20251118/25628425.html

Form 6-K CytoMed Therapeutics For: Nov 18

Tue, 18 Nov 2025 08:00:00 -0500

si-local-file:///var/storage/secattach/20251118/25628425.html

CytoMed Therapeutics secures $500,000 investment for subsidiary

Thu, 06 Nov 2025 08:04:53 -0500

CytoMed Therapeutics Limited (NASDAQ: GDTC) announced that ICH Capital Pte Ltd will invest up to $500,000 for a 10% post-money stake in its subsidiary LongevityBank Pte Ltd. The Singapore-based biopharmaceutical company said the investment is non-dilutive.

LongevityBank focuses on autologous therapies using personalized cellular banking services, while parent company CytoMed develops donor blood-derived allogeneic therapies. CytoMed currently operates an approved IND Phase I clinical trial in Singapore and a Phase II Investigator-Initiated Trial in India.

ICH Capital, founded in 2001, provides cross-border wealth and asset management solutions for ultra-high net worth individuals and institutions across Asia-Pacific. Chairman Vincent Toe stated the investment

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

Thu, 06 Nov 2025 08:00:00 -0500

SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd (“LongevityBank”) from ICH Capital Pte Ltd (“ICH Capital”).

Following the announcement dated August 28, 2025, the strategic vision is for LongevityBank to focus on autologous (using one’s own blood, cells and/or tissues) therapies

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

Thu, 06 Nov 2025 08:00:00 -0500

Following the announcement dated August 28, 2025, the strategic vision is for LongevityBank to focus on autologous (using one’s own blood, cells and/or tissues) therapies